>
Terns Pharmaceuticals Inc logo

TERN - Terns Pharmaceuticals Inc Share Price

$16.62 0.6  3.5%

Last Trade - 07/05/21

Sector
Healthcare
Size
Small Cap
Market Cap £298.9m
Enterprise Value £254.5m
Revenue £n/a
Position in Universe 3765th / 6858
Bullish
Bearish
Unlock TERN Revenue
Momentum
Relative Strength (%)
1m -11.2%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -41.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, TernsPharmaceuticals Inc revenues was not reported. Net lossapplicable to common stockholders decreased 57% to $29.4M.Lower net loss reflects Research and development -Balancing v decrease of 55% to $27.7M (expense), Generaland administrative - Balancing v decrease of 7% to $7.7M(expense). Basic Earnings per Share excluding ExtraordinaryItems increased from -$3.02 to -$1.29.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

TERN Revenue Unlock TERN Revenue

Net Income

TERN Net Income Unlock TERN Revenue

Normalised EPS

TERN Normalised EPS Unlock TERN Revenue

PE Ratio Range

TERN PE Ratio Range Unlock TERN Revenue

Dividend Yield Range

TERN Dividend Yield Range Unlock TERN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
TERN EPS Forecasts Unlock TERN Revenue
Profile Summary

Terns Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. The Company’s NASH pipeline includes multiple single-agent and combination therapy candidates that provide opportunities to address the multifaceted nature of NASH and provide clinical benefits for patients. The Company’s TERN-101 is a liver-distributed, non-bile acid Farnesoid X Receptor (FXR) that has demonstrated a profile and improved target engagement due to its sustained FXR activation in the liver but only transient FXR activation in the intestine. Its TERN-101 is in a Phase 2a clinical trial. Its TERN-201 is an inhibitor of vascular adhesion protein-1 (VAP-1) that has demonstrated target engagement in clinical trials. The TERN-201 is in Phase 1b clinical trial. Its TERN-501 is in Phase 1a clinical trial.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
No. of Shareholders: n/a
No. of Employees: 30
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 25,125,072
Free Float (0.0%)
Eligible for
ISAs
SIPPs
TERN Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for TERN
Upcoming Events for TERN
Frequently Asked Questions for Terns Pharmaceuticals Inc
What is the Terns Pharmaceuticals Inc share price?

As of 07/05/21, shares in Terns Pharmaceuticals Inc are trading at $16.62, giving the company a market capitalisation of £298.9m. This share price information is delayed by 15 minutes.

How has the Terns Pharmaceuticals Inc share price performed this year?

Shares in Terns Pharmaceuticals Inc are currently trading at $16.62 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Terns Pharmaceuticals Inc price has moved by % over the past year.

What are the analyst and broker recommendations for Terns Pharmaceuticals Inc?

There are no analysts currently covering Terns Pharmaceuticals Inc.

When will Terns Pharmaceuticals Inc next release its financial results?

Terns Pharmaceuticals Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Terns Pharmaceuticals Inc dividend yield?

Terns Pharmaceuticals Inc does not currently pay a dividend.

Does Terns Pharmaceuticals Inc pay a dividend?

Terns Pharmaceuticals Inc does not currently pay a dividend.

When does Terns Pharmaceuticals Inc next pay dividends?

Terns Pharmaceuticals Inc does not currently pay a dividend.

How do I buy Terns Pharmaceuticals Inc shares?

To buy shares in Terns Pharmaceuticals Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Terns Pharmaceuticals Inc?

Shares in Terns Pharmaceuticals Inc are currently trading at $16.62, giving the company a market capitalisation of £298.9m.

Where are Terns Pharmaceuticals Inc shares listed? Where are Terns Pharmaceuticals Inc shares listed?

Here are the trading details for Terns Pharmaceuticals Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: TERN
What kind of share is Terns Pharmaceuticals Inc?

Based on an overall assessment of its quality, value and momentum, Terns Pharmaceuticals Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Terns Pharmaceuticals Inc share price forecast 2021?

Shares in Terns Pharmaceuticals Inc are currently priced at $16.62. At that level they are trading at 74.49% discount to the analyst consensus target price of 0.00.

Analysts covering Terns Pharmaceuticals Inc currently have a consensus Earnings Per Share (EPS) forecast of -2.36 for the next financial year.

How can I tell whether the Terns Pharmaceuticals Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Terns Pharmaceuticals Inc. Over the past six months, the relative strength of its shares against the market has been %. At the current price of $16.62, shares in Terns Pharmaceuticals Inc are trading at -20.04% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Terns Pharmaceuticals Inc PE Ratio?

We were not able to find PE ratio data for Terns Pharmaceuticals Inc.

Who are the key directors of Terns Pharmaceuticals Inc?

We were unable to find the directors for Terns Pharmaceuticals Inc.

Who are the major shareholders of Terns Pharmaceuticals Inc?

Here are the top five shareholders of Terns Pharmaceuticals Inc based on the size of their shareholding:

OrbiMed Advisors, LLC Investment Advisor/Hedge Fund
Percentage owned: 15.09% (3.79m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 11.49% (2.89m shares)
Vivo Capital, LLC Venture Capital
Percentage owned: 10.65% (2.68m shares)
Deerfield Management Company, L.P. Hedge Fund
Percentage owned: 9.48% (2.38m shares)
Matthews International Capital Management, L.L.C. Investment Advisor
Percentage owned: 4.26% (1.07m shares)
Similar to TERN
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.